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Abstract
Cigarette smoking is the single most important epidemiological risk factor for bladder cancer but it is not known whether
exposure of urothelial cells to the systemic soluble contents of cigarette smoke is directly causative to bladder cancer and
the associated epigenetic changes such as tumor suppressor gene hypermethylation. We undertook this study to
investigate if long-term treatment of human urothelial cells with cigarette smoke extract (CSE) results in tumor suppressor
gene hypermethylation, a phenotype that was previously associated with long-term constant CSE treatment of airway
epithelial cells. We chronically treated an immortalized human urothelial cell line UROtsa with CSE using a cyclic daily
regimen but the cells were cultured in CSE-free medium between daily treatments. Bisulfite sequencing and real-time PCR
array-based methylation profiling were employed to evaluate methylation changes at tumor suppressor gene loci in the
chronically CSE-treated cells versus the passage-matched untreated control cells. The RUNX3 tumor suppressor gene
promoter was hypomethylated with a significant increase in proportion of the completely unmethylated haplotype after the
long-term CSE treatment; whereas RUNX3 promoter hypermethylation was previously reported for bladder cancers of
smokers. Hypomethylation induced by the long-term CSE treatment was also observed for the IGF2-H19 locus. The
methylation status at the PRSS8/prostasin and 16 additional loci however, was unaffected by the chronic CSE treatment.
Transient CSE treatment over 1 daily regimen resulted in transcriptional down-regulation of RUNX3 and H19, but only the
H19 transcription was down-regulated in the chronically CSE-treated urothelial cells. Transcription of a key enzyme in onecarbon metabolism, dihydrofolate reductase (DHFR) was greatly reduced by the long-term CSE treatment, potentially
serving as a mechanism for the hypomethylation phenotype via a reduced supply of methyl donor. In conclusion, chronic
cyclic CSE treatment of urothelial cells induced hypomethylation rather than hypermethylation at specific loci.
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development of papillary, low-grade, non-invasive urothelial
carcinomas versus those to the development of the invasive type
are believed to be distinct and mutually exclusive. Aberrant DNA
methylation correlates with increased bladder tumor invasion and
progression and is implicated for a causative role [3]. In the nonmuscle invasive urothelial carcinomas, DNA methylation at six of
twenty cancer-associated genes examined in a 105-patient cohort
was shown to associate with recurrence, while methylation at one
of the genes predicts prolonged disease-free interval [4].
In bladder cancers, promoter DNA hypermethylation in tumor
suppressor genes has been associated with cigarette smoking [5].
Promoter methylation in the p16-INK4A gene in bladder cancers
was associated with cigarette smoking, with a greater than doubled
risk for smokers versus nonsmokers, and with a greater risk in
patients with more recent history of smoking [6]. DNA methylation at the RUNX3 (runt-related transcription factor 3) tumor
suppressor gene naturally increases with age and occurs significantly earlier in bladder cancers of smokers than nonsmokers [7].
The associated effects of cigarette smoking on bladder cancer

Introduction
Cigarette smoking is the single most important epidemiological
risk factor for bladder cancer as smokers have a four-fold higher
risk versus nonsmokers; while about half of bladder cancers among
men and women may be associated with or attributed to cigarette
smoking [1]. The mainstream cigarette smoke or the cigarette
smoke condensate/extract (CSC/CSE) has been shown to cause
all sorts of genomic DNA damages in experimental animals as well
as in humans, and is regarded as a systemic human mutagen with
a direct role in causing eight different cancers including that of the
urinary bladder [2]. In recent years, the role of epigenetic/
epigenomic modifications in carcinogenesis, at all stages including
initiation, promotion, and progression has been recognized.
Bladder cancer was the model with which Peter Jones and
colleagues expanded the ‘‘Knudson two-hit hypothesis’’ to include
the mechanism of tumor suppressor silencing by epigenetic
modifications in the consideration in addition to the mechanism
of DNA damages [3]. The molecular pathways that lead to the
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development appear direct, early, and more aggressive than the
effects of other factors.
While the epidemiological evidence is strong for a causative role
of cigarette smoking in bladder cancer development and in
epigenetic changes in bladder cancer specimens, there is no direct
proof that exposure of urothelial cells to cigarette smoke causes
these changes. A recent study reported that long-term exposure of
airway epithelial cells to cigarette smoke condensate/extract
resulted in cellular transformation marked by increased soft-agar
clonogenicity and induced hypomethylation of repetitive DNA but
hypermethylation of tumor suppressor genes; epigenetic changes
that are consistent with pulmonary carcinogenesis [8]. In our study
presented here, we exposed urothelial cells to cigarette smoke
extract (CSE) and evaluated CpG methylation changes in two
marker genes, RUNX3 and PRSS8/prostasin in the CSE-treated
cells versus the untreated control cells. The PRSS8/prostasin
serine protease is down-regulated in bladder cancer and its loss in
bladder cancer cell lines correlates with promoter DNA hypermethylation [9]. We then performed a methylation-specific PCR
array analysis of 24 human tumor suppressor genes on the CSEtreated cells and the untreated control cells. DNA hypomethylation in the RUNX3 promoter, the IGF2 (insulin-like growth factor
II) gene DMR (differentially methylated region), and the H19
CBS6 (CTCF-binding site 6) was observed in association with
long-term CSE treatment of urothelial cells; along with downregulation of dihydrofolate reductase (DHFR) expression.

Bisulfite sequencing
High-molecular-weight genomic DNA was extracted from the
UROtsa cell samples as described previously [13]. Bisulfite (BS)
treatment of the genomic DNA was performed by using the
EpiTect Bisulfite Kit (QIAGEN, Valencia, CA) and the supplier’s
protocol. For each sample, 2 mg of starting genomic DNA were
used for the BS treatment. For amplification of the RUNX3 and
PRSS8 gene fragments for sequencing analysis, 10% of each BStreated DNA sample was used, with the primers listed below for
each target gene.
PRSS8: forward: GGGGGTATAATTGGTTTGAGATAAT
reverse: CCTCCCAAAAATAACTACACCTACC
The primers for RUNX3 promoter fragment amplification off
the BS-DNA were described previously [7].
The top strand of the BS-treated DNA was amplified for each
target gene, using the GoTaq Hot Start Polymerase (Promega,
Madison, WI). Amplification of the IGF2 DMR and H19 CBS6
was performed as described previously [14]. The PCR amplicons
were purified using the QIAEX II Gel Extraction Kit (QIAGEN)
after agarose gel electrophoresis, and cloned into the pGEM-T
Easy plasmid (Promega). For each sample, 60 independent clones
were selected for sequencing, performed by Eton Bioscience
(Research Triangle Park, NC).

Methylation PCR array analysis
A Methyl-Profiler DNA Methylation PCR Array for Human
Tumor Suppressor Genes, Signature Panel MeAH-551A (QIAGEN) was used to analyze the methylation changes of 24 genes
using the supplier’s protocol.

Materials and Methods
Cell culture
The immortalized human urothelial cell line UROtsa was
cultured as described previously [9].

Quantitative real-time PCR analysis
Total cellular RNA isolation, reverse transcription and real-time
PCR were performed as described previously [10]. The primers
used in the quantitative evaluation of gene expression were:
H19: forward: CGTCCCTTCTGAATTTAATTTG
reverse: ACACTCGTACTGAGACTC
DNMT1: forward: GAACCAACACCCAAACAG
reverse: TTCTCGTCTCCATCTTCG
The primers used for RUNX3, IL-6, DHFR, and 18S rRNA
were described previously [15,16,17,18]. The relative mRNA
expression of each target gene was calculated as the copy number
per 1/100 18S rRNA copy.

CSE preparation
The preparation of CSE was described previously [10]. Briefly,
research-reference cigarettes (1R3F, 1.16 mg nicotine and 15 mg
tar) were obtained from the University of Kentucky, Tobacco
Research and Development Center, and kept in a refrigerated dry
environment, but equilibrated to room temperature before use.
CSE was routinely prepared by bubbling one unfiltered cigarette
through 25 ml of serum-free DMEM/F12 medium [11]. The CSE
stock medium was then filtered through a 0.22-mm filter to remove
particles and microbes. Large stocks of CSE were prepared as
described above and designated as 100%, and stored at –80uC in
small aliquots for use within two weeks. Each aliquot was used only
once after thawing. The 100% CSE prepared by the procedures
described above was estimated to represent approximately 1/4 of
the average smoker’s plasma concentration of soluble cigarette
smoke contents [12]. The CSE was diluted to the desired
concentrations in culture medium when used.

Western blot analysis
Evaluation of protein expression changes by western blot
analysis was performed as described previously [10]. The
antibodies used were DHFR (used at 1:1,000 dilution) and
GAPDH (glyceraldehyde 3-phosphate dehydrogenase, used at
1:5,000 dilution) (Santa Cruz Biotechnology). The detected signals
were quantified by densitometric analysis using an Alpha Imager
2200 (Alpha Innotech Corporation) with the AlphaEaseFC
Software (Version 3.2.1). The relative protein expression of
DHFR in each sample was calculated using the GAPDH protein
level as the normalization standard.

CSE treatment of cells
UROtsa cells were seeded in a T25 flask and grown to 60-70%
confluence prior to treatment. In one cycle of treatment, the cells
were treated for 15 minutes with 50% CSE diluted in serum-free
DMEM/F12 medium, and then cultured for 1 hour in CSE-free
fresh growth medium (DMEM/5%FBS/1 mM Glucose). The
treatment was repeated for 3 cycles per day and between daily
treatments the cells were cultured in the CSE-free growth
medium. The daily CSE treatments were performed for 4 days
consecutively before the cells were passaged (at 1:5) into a new
T25 flask for continuation of the long-term treatment.

PLOS ONE | www.plosone.org

Statistical analysis
Student’s t-test was used to evaluate comparisons of two means,
whereas Z-test was used to evaluate comparisons of two
percentages. Differences were considered statistically significant
when p,0.05.
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Results

CpG methylation in the PRSS8 promoter is unaffected in
urothelial cells after long-term CSE exposure

The RUNX3 promoter is hypomethylated in urothelial
cells after long-term CSE exposure

The PRSS8 BS DNA amplicon subjected to sequencing analysis
contains 9 CpG sites in the promoter region of this gene. We have
shown previously that hypermethylation at some of these sites
(CpG-3 and CpG-5) is causative to PRSS8 expression downregulation in human bladder, breast, and prostate cancer cell lines
[9,13,19]. Between the UROCSE-p32 cells and the UROtsa-p32
cells, no methylation changes at any of the CpG sites reached
statistical significance (p.0.05, Figure 2). One completely
unmethylated (UM) amplicon was among the independent clones
sequenced for the UROCSE-p32 cells but none was seen for the
UROtsa-p32 cells.

For the chronic treatment regimens we needed to determine the
concentration of CSE for use so as to produce the maximum effect
on the marker gene expression during the treatment intervals but
with the least toxicity on the cells. We used RUNX3 mRNA
expression down-regulation as an indicator for the effects of CSE
treatment at various concentrations, and cell growth as a measure
of toxicity, as described in a previous study [10]. We tested 10%,
20%, 50% and 100% CSE by these criteria, and 50% CSE was
found to down-regulate RUNX3 mRNA expression by the
greatest margin without causing major impediments on cell
proliferation (data not shown).
The RUNX3 BS DNA amplicon subjected to sequencing
analysis contains 17 CpG sites in the promoter region of this gene,
including 2 sites (designated as CpG-1 and CpG-2 in this
amplicon) previously shown to be hypermethylated in bladder
cancer specimens from smokers [7]. We examined the RUNX3
promoter in CSE-treated UROtsa cells of the 32nd passage
(designated as UROCSE-p32), and in passage-matched control
cells (UROtsa-p32) cultured in CSE-free growth medium. The
data were first analyzed for each individual CpG site by
calculating the percentage of independent clones presenting the
methylated cytosine. Of the 17 CpG sites examined, 4 sites, CpG1, -5, -6, and -12, were found to be hypomethylated in the
UROCSE-p32 cells versus the UROtsa-p32 cells (p,0.05; Figure
1A). Methylation changes at all other CpG sites did not reach
statistical significance (p.0.05).
We then analyzed each clone to determine if there were
epigenetic haplotype changes associated with the CSE treatment.
As shown in Figure 1B, approximately 23% (14/61) of the
RUNX3 BS DNA clones of the UROCSE-p32 cells were
completely unmethylated (UM) at all 17 CpG sites, whereas the
UROtsa-p32 cells had less than 2% (1/58) completely unmethylated clones.

Methylation PCR array analysis reveals hypomethylation
at the IGF2 gene locus
The Methyl-Profiler array with 24 human tumor suppressor
genes was applied to analyze the genomic DNA of the UROCSEp32 and the UROtsa-p32 cells. Of the 21 genes that had successful
amplification according to the supplier’s quality control standards,
17 genes had less than 1% of change in either Hyper- (HM),
Intermediately- (IM), or Un-methylated (UM) DNA between the
CSE-treated cells and the untreated control cells (Figure S1).
Three (3) other genes had 2–11% of changes in their methylation
status between the two cell types. The methylation status change of
IGF2 was the greatest. The Hyper-methylated (HM) IGF2 DNA
was at ,61% in the untreated control UROtsa-p32 cells, but at
50% in the CSE-treated UROCSE-p32 cells; with a corresponding change of Un-methylated (UM) DNA from ,39% to 50%.
As IGF2, along with the neighboring H19 gene, are genomically
imprinted in humans, we interrogated in further detail the
methylation status changes in the CSE-treated and the untreated
control UROtsa cells by amplifying the IGF2 DMR and the H19
CBS6 from the BS DNA for sequencing analysis. The IGF2 DMR
BS DNA amplicon contains 3 CpG sites, and we grouped the
clones by their methylation status as Hyper-methylated (HM, 3/3),
Intermediately-methylated (IM, 1/3, or 2/3), and Un-methylated

Figure 1. Epigenetic changes at the RUNX3 locus in UROtsa cells chronically treated with CSE. A. Percentage of methylation at 17 CpG
sites in the RUNX3 promoter determined by bisulfite sequencing of genomic DNA extracted from UROtsa cells chronically treated with CSE, UROCSEp32 (32nd passage) and from untreated control cells, UROtsa-p32 (32nd passage). Percentage of methylation was calculated by the number of
methylated cytosines at each CpG site observed in the total number of independent clones sequenced for each BS DNA amplicon, for UROtsa-p32,
n = 58; and for UROCSE-p32, n = 61. The encircled sites presented hypomethylation in the UROCSE-p32 cells (p,0.05). B. Fractions of completely
unmethylated (UM) haplotype in the UROtsa-p32 and the UROCSE-p32 cells.
doi:10.1371/journal.pone.0065513.g001
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Figure 2. Epigenetic changes at the PRSS8 locus in UROtsa cells chronically treated with CSE. Percentage of methylation at 9 CpG sites in
the PRSS8 promoter determined by bisulfite sequencing of genomic DNA extracted from UROtsa cells chronically treated with CSE, UROCSE-p32 (32nd
passage) and from untreated cells, UROtsa-p32 (32nd passage). Percentage of methylation was calculated by the number of methylated cytosines at
each CpG site observed in the total number of independent clones sequenced for each BS DNA amplicon, n = 60 for both UROtsa-p32 and UROCSEp32.
doi:10.1371/journal.pone.0065513.g002

(UM, 0/3). As shown in Figure 3A, long-term CSE treatment had
a hypomethylation effect on the IGF2 DMR, increasing the UM
DNA from ,26% (15/58) in the UROtsa-p32 cells to ,47% (27/
58) in the UROCSE-p32 cells (p,0.05). The H19 CBS6 BS DNA
amplicon contains 23 CpG sites. We dichotomized the methylation status as Hyper-methylated (HM) versus Un-methylated (UM)
because all clones for both the UROCSE-p32 and the UROtsap32 cells were either .70% methylated (HM) or completely
unmethylated (UM) at the 23 sites, with one exception among the
independent clones sequenced for the UROCSE-p32 cells. This
clone was ,35% (8/23) methylated and was counted as UM. As
shown in Figure 3B, H19 CBS6 is hypomethylated in the
UROCSE-p32 cells when compared to the UROtas-p32 cells
(p,0.05).
Two loci, RARB (retinoic acid receptor beta) and RASSF1 (Ras
association domain family 1), showed hypermethylation in airway
epithelial cells following chronic constant CSE treatment [8], but
are minimally hypermethylated in the chronically but cyclically
CSE-treated urothelial cells (Figure S1). The RUNX3 locus
however, was also reported to have a ,1% methylation change by
the array analysis (Figure S1).

passage UROtsa cells (p34, UROtsa-HP). In the UROtsa-LP and
the UROtsa-HP cells, transient CSE treatment resulted in reduced
RUNX3 mRNA expression, by ,42% and ,37%, respectively
(p,0.05) (Figure 4A). Passaging had no effect on RUNX3 mRNA
expression (comparing UROtsa-LP and UROtsa-HP, p.0.05).
The PRSS8 mRNA expression was not affected by the chronic
CSE treatment, whereas the IGF2 mRNA expression level fell
below the sensitivity limit of the assay (data not shown). The H19
mRNA expression was lower in the UROCSE-p35 cells as
compared to the UROtsa-p34 (HP) cells by ,63% (p,0.05,
Figure 4B). Transient CSE treatment resulted in reduced H19
mRNA expression in the UROtsa-LP and UROtsa-HP cells, by
,68% and ,74%, respectively (p,0.05, Figure 4B). Passaging
however, had an apparently up-regulatory effect on H19 mRNA
expression, resulting in a ,3-fold higher expression in the
UROtsa-HP cells versus the UROtsa-LP cells (p,0.05, Figure
4B).
We evaluated the interleukin-6 (IL-6) mRNA expression in the
five cell types described above to validate the CSE treatments, as
CSE has been shown to up-regulate IL-6 expression in cultured
cells [20]. In both the UROtsa-LP and the UROtsa-HP cells, the
transient CSE treatment resulted in IL-6 mRNA up-regulation, to
,1.8 and ,2.2 fold, respectively (p,0.05, Figure 4C). But there
was no difference of IL-6 mRNA level between the UROCSE-p35
and the UROtsa-p34 (HP) cells (p.0.05, Figure 4C). IL-6 mRNA
expression was ,3.6 fold higher in the UROtsa-HP cells than in
the UROtsa-LP cells (p,0.05, Figure 4C).

Hypomethylated loci show corresponding repression of
expression in the chronically CSE-treated cells
We investigated if the DNA methylation changes that we
observed in the chronically CSE-treated UROtsa cells are
associated with transcriptional changes of the genes evaluated.
The RUNX3 mRNA expression was not affected by the chronic
CSE treatment, when evaluated between UROCSE-p35 and
UROtsa-p34 (shown as UROtsa-HP in Figure 4A). We also
evaluated RUNX3 mRNA expression in response to a transient
CSE treatment for 3 treatment cycles but 1 day only, using lowpassage UROtsa cells (p8, shown as UROtsa-LP) as well as high-
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DHFR expression was reduced in association with CSE
treatment
To explore the potential molecular mechanisms underlying the
hypomethylation phenotypes observed at the RUNX3 and the
IGF2-H19 loci in the chronically CSE-treated urothelial cells, we
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Figure 3. Epigenetic changes at the IGF2-H19 locus in UROtsa cells chronically treated with CSE. A. Percentage of methylation at 3 CpG
sites in the IGF2 DMR determined by bisulfite sequencing of genomic DNA extracted from UROtsa cells chronically treated with CSE, UROCSE-p32
(32nd passage) and from untreated cells, UROtsa-p32 (32nd passage). HM: hypermethylated with 3 of 3 CpG sites presenting methylation; IM:
intermediately methylated with 2 or 1 of 3 CpG sites presenting methylation; UM: unmethylated with 0 of 3 CpG sites presenting methylation; n = 58
for both UROtsa-p32 and UROCSE-p32. The increase of UM DNA at this locus in the UROCSE-p32 cells was statistically significant (p,0.05), as
indicated in the figure. B. Percentage of methylation at 23 CpG sites in the H19 CBS6 determined by bisulfite sequencing of genomic DNA extracted
from UROtsa cells chronically treated with CSE, UROCSE-p32 (32nd passage) and from untreated cells, UROtsa-p32 (32nd passage). HM:
hypermethylated with .70% of the CpG sites presenting methylation; UM: unmethylated with 0 of 23 CpG sites presenting methylation; n = 60 for
both UROtsa-p32 and UROCSE-p32. One clone presenting 8 methylated CpG sites of the 23 was observed for the UROCSE-p32 cells and was counted
as UM. The increase of UM DNA at this locus in the UROCSE-p32 cells was statistically significant (p,0.05), as indicated in the figure.
doi:10.1371/journal.pone.0065513.g003

correlates with bladder cancer progression [9]. The RUNX3
promoter however, showed hypomethylation at CpG-1 in the
urothelial cells chronically exposed to CSE, whereas this same site
was found to be hypermethylated in bladder cancer specimens of
smokers.
The time course of CSE treatment of the urothelial cells in our
study is comparable to the time course of CSE treatment of the
airway epithelial cells in the study by Liu et al. [8], in which
tumorigenic transformation and hypermethylation of tumor
suppressor genes were reported for the chronically CSE-treated
airway epithelial cells. At between the 32nd and the 35th passages,
the UROtsa cells chronically treated with CSE by our regimen (3
cycles a day with 15 minutes of exposure per cycle using 50%
CSE) were not transformed as no colonies could form in soft agar
anchorage-independent growth assays (data not shown). The
UROtsa cell line is a transformation-competent cell line, capable
of forming colonies in soft agar upon tumorigenic transformation,
as shown previously by others [21]. With these observations, we
tentatively conclude that chronic CSE treatment alone is not
sufficient to transform cultured urothelial cells.
There is however, a major technical difference in our urothelial
cell chronic CSE treatment regimen versus that used in the study
by Liu et al. to treat the airway epithelial cells, which were
constantly exposed to CSE for the 5 months of treatment with
daily changes of CSE-supplemented medium [8]. We reason that
our cyclic treatment regimen is more appropriate for evaluating
the effects of systemic soluble cigarette smoke contents on tissues
that are not directly exposed to the cigarette smoke. Constant CSE
exposure would effectively simulate non-stop smoking whereas the
cyclic CSE exposure would more closely mimic the behavioral
patterns of smokers over a 24-hour daily period. It is therefore, not
surprising that loci with .100% increase in methylation in the
chronically CSE-treated airway epithelial cells under constant
exposure, e.g., RARB and RASSF1 [8], were only minimally
affected in the urothelial cells under cyclic exposure (Figure S1).
We were unable to perform a direct comparison of methylation

evaluated the mRNA expression of DNA methyltransferases
(DNMT1, DNMT3A, and DNMT3B), and of the key players in
folate metabolism (dihydrofolate reductase, DHFR; folate receptor, FOLR1; and folate transporter, RFC1). The DNMT1 mRNA
expression was unaffected by either the chronic or the transient
CSE treatment (p.0.05, Figure 5A), whereas the DNMT3A and
DNMT3B mRNA levels fell below the sensitivity limit of the assay
(data not shown).
The DHFR mRNA expression was lower in the UROCSE-p35
cells as compared to the UROtsa-p34 (HP) cells, by ,66%
(p,0.05, Figure 5B). Transient CSE treatment resulted in
reduced DHFR mRNA expression as well, in both the UROtsaLP and the UROtsa-HP cells, by ,36% and ,31%, respectively
(p,0.05, Figure 5B). Passaging had no effect on DHFR mRNA
expression (comparing UROtsa-LP and UROtsa-HP, p.0.05).
The FOLR1 and RFC1 mRNA levels fell below the sensitivity
limit of the assay (data not shown). The down-regulation of DHFR
transcription by the CSE treatments was accompanied with a
corresponding down-regulation of DHFR protein expression, as
shown in Figure 5C.

Discussion
We undertook this study to determine if direct exposure of
cultured urothelial cells to CSE over the long term, mimicking the
exposure of urothelial cells to the systemic soluble contents of
cigarette smoke in smokers, would have epigenetic modification
effects on the urothelial cells. The study design was to monitor the
epigenetic changes in two tumor suppressor genes, RUNX3 and
PRSS8, and follow up with a screening for epigenetic changes in
more tumor suppressor genes if CSE-induced changes were to be
observed in the RUNX3 and PRSS8 marker genes. We had fully
expected that both of these marker genes would present a
hypermethylation phenotype in the chronically CSE-treated
urothelial cells as RUNX3 hypermethylation in bladder cancer
is associated with smoking [7] and PRSS8 hypermethylation
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Figure 4. Expression changes of genes presenting CSE-induced hypomethylation in the CSE-treated UROtsa cells. A. RUNX3 mRNA
expression in UROtsa cells transiently or chronically treated with CSE. Data represent RUNX3 mRNA copy numbers relative to 1/100 of the 18S rRNA
copy number, determined as the mean of three independent experiments with standard errors shown by the error bars. UROtsa-LP: UROtsa cells
cultured in CSE-free medium, 8th passage; UROtsa-LP CSE: UROtsa-LP cells treated for 1 day with CSE. UROtsa-HP: UROtsa cells cultured in CSE-free
medium, 34th passage; UROtsa-HP CSE: UROtsa-HP cells treated for 1 day with CSE. UROCSE-p35: UROtsa cells chronically treated with CSE, 35th
passage. Statistically significant differences between the datum columns are as indicated in the figure (n = 3, p,0.05). B. H19 mRNA expression in
UROtsa cells transiently or chronically treated with CSE. Statistically significant differences between the datum columns are as indicated in the figure
(n = 3, p,0.05). C. IL-6 mRNA expression in UROtsa cells transiently or chronically treated with CSE. Statistically significant differences between the
datum columns are as indicated in the figure (n = 3, p,0.05).
doi:10.1371/journal.pone.0065513.g004

changes in UROtsa cells treated cyclically versus those treated
constantly over the long term because the 50% CSE concentration
used in the cyclic regimens proved to be much too cytotoxic when
present in the cultures constantly and would not have allowed
successive passaging of the treated cells. The wisdom of using the
cyclic or the constant regimen for chronic CSE treatment of
cultured cells to study the effects of CSE on these cells may be
open for debate and the cell type differences between the airway
epithelial and the urothelial cells notwithstanding, the research
field should now carefully consider the differences in the
phenotypes induced by the two different treatment regimens.
It must also be emphasized that cigarette smoke contents may
undergo metabolic activation in the body and thus the in vivo
effects on the cells would be brought forth by the original
components as well as the metabolites, whereas treating cultured
cells in vitro with CSE may or may not produce the effects of the
metabolites depending on the cell types. Despite this limitation,
adding CSE to the culture medium to test its immediate effects on
cultured cells in vitro was used by many published studies that
provided meaningful molecular and cellular mechanistic insights
on the impact of CSE to the cells in various physiological contexts
[2,8,10,11].
There is a possibility that the Methyl-Profiler DNA Methylation
PCR Array that we employed for evaluation of methylation
changes at select tumor suppressor gene loci could report false
negative results. The RUNX3 locus was among the 24 genes in the
Methyl-Profiler array, but it was determined to have a rather
minimal hypomethylation change in the UROCSE-p32 cells as
compared to the UROtsa-p32 cells when the array analyses were
performed (Figure S1). In addition, the methylation status of the
RUNX3 gene reported for the untreated UROtsa cells was ,99%
hypermethylated, in apparent contradiction to the previous reports
by others showing an unmethylated to intermediately methylated
status at this locus in normal urothelial cells [7,22]. The study by
Kim et al. [22] examined the CpG sites in the immediately
upstream region of the RUNX3 gene, from nucleotide -211 to
nucleotide -61; whereas the region inspected in the study by Wolff
et al. [7] was from nucleotide -820 to nucleotide -601, further
upstream. Kim et al. [22] used direct sequencing to determine the
methylation status of all 25 CpG sites in the (2211 to 261) region;
whereas Wolff et al. [7] looked at the average of 2 of 17 CpG sites
in the (2820 to 2601) region, using the method of methylationsensitive single nucleotide primer extension. In our study the
(2820 to 2601) region was examined and the methylation status
of all 17 CpG sites was determined, with CpG-1 and CpG-2 being
the sites inspected in Wolff et al. [7]. The Methyl-Profiler array is
reporting on the average of detectable CpG sites over a region of
3,478 bp in the RUNX3 promoter (including the 2820 to 2601
region) and it relies on the presence of cleavage sites for
methylation-sensitive and methylation-dependent restriction endonucleases for the detection. We and Kim et al. [22] inspected
different regions of the RUNX3 gene and it is not unexpected that
different patterns of methylation may be observed in normal
urothelial cells. Likewise, the Methyl-Profiler may also be
PLOS ONE | www.plosone.org

reporting on CpG sites that are outside of our region of inspection,
giving a hypermethylated pattern. The actual sites reported on by
the assay are proprietary information and not available to us. Our
results on the methylation status of the RUNX3 CpG-1 and CpG2 in the untreated control UROtsa cells, on the other hand, are
fairly consistent with that reported by Wolff et al. [7]. We observed
an average of 31% methylation in this cell line for these two CpG
sites, whereas in seven matched normal/tumor cases reported in
Wolff et al. [7], the average levels of methylation at these two sites
were between 3224% in the normal tissues but between 45275%
in the tumor tissues. For all 17 sites inspected in our study, only
CpG-5 showed .60% methylation in the untreated UROtsa cells,
but all other sites have ,40% methylation, with 12 of the 17 sites
at below 20% methylation. We consider the UROtsa cell line an
appropriate model of normal urothelial cells for studying RUNX3
promoter methylation changes impacted by CSE. But even with
the limitation of reporting false negatives and results that may
appear inconsistent with previously published data for known loci,
the Methyl-Profiler identified the IGF2 locus as presenting a
hypomethylated phenotype in the chronically CSE-treated cells, a
phenotype that was confirmed in the ensuing BS DNA sequencing
of the IGF2 DMR.
Whereas hypermethylation in the RUNX3 tumor suppressor
gene promoter is associated with bladder cancers of smokers [7],
our chronic CSE treatment of cultured urothelial cells induced a
hypomethylated phenotype at this locus over 4 of 17 CpG sites,
with a significant increase in the fraction of the completely
unmethylated haplotypes. So not only was CSE treatment unable
to transform the urothelial cells the epigenetic changes in the
RUNX3 tumor suppressor gene were of the opposite kind. One
possible explanation is that the hypomethylation effect of CSE on
RUNX3 in the cultured urothelial cells is the direct effect of CSE;
but the hypermethylation of RUNX3 in bladder cancers of
smokers is caused by additional indirect mediators, such as
inflammatory cytokines. Indeed, serum concentrations of IL-6
were shown to be significantly increased in rats chronically treated
with CSE [23]; while IL-6 could induce the expression of DNMT1
[24]. The actions of the inflammatory cytokines, either produced
innately by the epithelial cells or perhaps more predominantly by
the immune cells, may also be the necessary factors needed for
cellular transformation. For example, IL-6 enhances urothelial
cellular transformation in vitro [25]. Transformed cells have been
shown to have concurrent up-regulation of DNA methyltransferases [26], so at the stage of fully transformed bladder cancer cells
the RUNX3 promoter may after all manifest the hypermethylated
phenotype in smokers. Our transient CSE treatment regimen (3
cycles but only 1 day) did result in an increase of IL-6 expression
but the chronically CSE-treated cells did not show any CSEassociated IL-6 up-regulation other than what could be associated
with passaging (Figure 4C). Previous studies showing increased
IL-6 expression as a result of chronic CSE treatment involved
constant exposure to this complex agent [23] but in our study we
performed intermittent treatments with no CSE presence when
the chronically treated cells were cultured between daily regimens.
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Figure 5. Changes of DNMT1 and DHFR expression in the CSE-treated UROtsa cells. A. DNMT1 mRNA expression in UROtsa cells
transiently or chronically treated with CSE. Data represent DNMT1 mRNA copy numbers relative to 1/100 of the 18S rRNA copy number, determined
as the mean of three independent experiments with standard errors shown by the error bars. UROtsa-LP: UROtsa cells cultured in CSE-free medium,
8th passage; UROtsa-LP CSE: UROtsa-LP cells treated for 1 day with CSE. UROtsa-HP: UROtsa cells cultured in CSE-free medium, 34th passage; UROtsaHP CSE: UROtsa-HP cells treated for 1 day with CSE. UROCSE-p35: UROtsa cells chronically treated with CSE, 35th passage. B. DHFR mRNA expression
in UROtsa cells transiently or chronically treated with CSE. Statistically significant differences between the datum columns are as indicated in the
figure (n = 3, p,0.05). C. DHFR protein expression in UROtsa cells transiently or chronically treated with CSE. The images presented here represent the
results from three independent experiments. For samples in Lanes 1 and 2, 40 mg of total protein were loaded in each lane; for samples in Lanes 3–5,
15 mg of total protein were loaded in each lane. After normalizing the DHFR signal intensities to the corresponding GAPDH signal intensities, the
relative DHFR signal intensity in the untreated cells was assigned as 1.00 and the relative DHFR signal intensities of the CSE-treated cells are as
indicated in the figure.
doi:10.1371/journal.pone.0065513.g005

In our transient treatments the predicted IL-6 up-regulation
phenotype was observed and we believe that the CSE treatment
itself was appropriately performed. We at present do not have a
testable hypothesis as to why the intermittent chronic treatment of
UROtsa cells failed to up-regulate IL-6 relatively to the passagematched untreated cells. We are performing experiments to
determine if chronically treating the UROtsa cells with exogenous
IL-6 or other inflammatory cytokines might be sufficient to
transform the cells and/or induce hypermethylation.
CSE’s hypomethylation effect in the urothelial cells appears to
be gene-specific, as the IGF2-H19 locus also showed a significantly
reduced level of methylation in the CSE-treated cells along with
RUNX3 but methylation at the PRSS8 locus or 16 other loci
evaluated on the Methyl-Profiler array was not affected by the
chronic CSE treatment. The hypomethylation of the RUNX3 and
the IGF2-H19 loci may be characteristic of the responses of
urothelial cells to CSE exposure without cellular transformation,
which apparently requires more than just the CSE treatment. In
the chronically CSE-treated UROtsa cells, the expression of the
maintenance methylation enzyme, DNMT1, did not show CSEassociated changes (Figure 5A) but the expression of DHFR was
significantly reduced at both the mRNA and the protein levels
(Figures 5B and 5C). The reduced DHFR expression would
result in a reduced supply of tetrahydrofolate, and in turn a
reduced supply of methyl donor and a reduced rate of
maintenance methylation, whereas upon continued DNA replication, the fractions of completely unmethylated haplotypes would
then increase. This may account for the phenotype observed in
our chronically CSE-treated cells. Alternatively, the CSE-associated hypomethylation phenotypes may be a result of higher
activities of the double-stranded DNA break repair (DSBR) system
at play. CSE is known to cause double-stranded DNA breaks when
applied to human cells in culture [27]. DSBR has recently been
shown to play a role in epigenetic reprogramming, producing
completely unmethylated haplotypes in cultured cells upon
introduction of DSBs [28]. CSE’s effect on DNA strand breaks
is reversible in 24 hours upon removal of the CSE [29], allowing
the cells to have at least the opportunity to recover from the
damage and survive. In our case, our repetitive daily regimens of
CSE treatment are expected to repeatedly produce the strand
break and repair cycle, enabling the DSBR-mediated epigenetic
reprogramming to generate the completely unmethylated haplotypes in the chronically CSE-treated cells at a much greater
proportion (.20%, Figure 1B) than those naturally occurring in
the untreated control cells (, 2%, Figure 1B). But clearly, both
RUNX3 and PRSS8 were found to be hypermethylated in
bladder cancers or bladder cancer cell lines, with RUNX3
hypermethylation directly associated with bladder cancers of
smokers. With DSBR as a potential molecular mechanism to
produce the hypomethylation phenotype, there is no direct conflict
between the early-phase hypomethylation of select genes in CSEtreated urothelial cells and the hypermethylation of the same genes
PLOS ONE | www.plosone.org

in the bladder cancer cells. Smokers are essentially playing the
Russian Roulette with their urothelial cells by having the cyclic
peaks of systemic CSE, which is expected to cause the DSBs and to
activate the DSBR. In the early phase, the DSBR will produce the
hypomethylation effect observed in our study in the marker genes
evaluated. Eventually, some of the cells will not fully repair the
DNA damage and will be transformed. The chromosomal DNA
will then be at the mercy of the DNA methyltransferases which are
expected to be up-regulated in the transformed cells, and the
hypermethylation phenotype observed in bladder cancers may
thus be manifested.
An alternative candidate mechanism for the CSE-induced
hypomethylation phenotype is the involvement of enzymes that
participate in active demethylation via various pathways such as
oxidative demethylation, deamination of 5-methylcytosine to
thymine followed by base excision repair, and nucleotide excision
repair [30]. To test this hypothesis, we evaluated the effects of CSE
on the expression of the TET (ten-eleven translocation) family
proteins (TET1, TET2, and TET3), AID (activation-induced
deaminase), the APOBEC (apolipoprotein B mRNA editing
enzyme catalytic polypeptide) family protein APOBEC3a, and
GADD45a (growth arrest and DNA-damage-inducible 45a).
When the chronically CSE-treated UROCSE cells were compared
with passage-matched untreated control UROtsa cells, none of the
genes tested above showed statistically significant differential
expression (data not shown). Thus it is unlikely that direct active
demethylation could serve as a mechanism for the CSE-induced
hypomethylation in the urothelial cells.
An immediately testable hypothesis for a molecular mechanism
of the CSE-induced DHFR down regulation is that this effect is
mediated by free radicals such as hydrogen peroxide, which has
been known to be produced when cigarette smoke is bubbled
through phosphate-buffered saline [31]; whereas DHFR downregulation by hydrogen peroxide had previously been reported as
a major molecular pathway regulating the DHFR gene expression
[32]. We performed western blot analysis on UROtsa cells that
were untreated, treated with CSE (by the intermittent regimen),
treated with a free radical scavenger (catalase or glutathione), and
treated with CSE but pretreated and treated along with the free
radical scavengers. We were unable to show a rescue of the CSEinduced DHFR down-regulation with the free radical scavengers,
while catalase rescued DHFR expression down-regulation induced
by hydrogen peroxide treatment (data not shown), as previously
described by others for another cell type [32]. The hydrogen
peroxide produced by bubbling cigarette smoke through culture
medium does not appear to be a major factor to cause the DHFR
down-regulation. Alternative mechanisms of the CSE-induced
DHFR down-regulation will be sought after in our future studies.
When we began this study our working hypothesis was that the
RUNX3 tumor suppressor gene promoter is hypermethylated in
bladder cancers of smokers so chronically treating normal
urothelial cells with CSE might also lead to RUNX3 promoter
9
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hypermethylation, which is expected to down-regulated its
transcription [33]. In the chronically CSE-treated urothelial cells,
however, we observed a hypomethylation rather than a hypermethylation phenotype at the RUNX3 locus, with no apparent
changes of transcription (Figure 4A). The UROtsa cells present a
relatively low level of methylation at the RUNX3 gene, as stated
above. Whereas a hypermethylation change could result in a
down-regulation of RUNX3 expression [33], the hypomethylation
change induced by the chronic CSE treatment is not expected to
produce such a phenotype. On the other hand, the baseline
methylation at RUNX3 in this cell line could have permitted the
normal levels of expression thus the hypomethylation, most
significantly in the form of the unmethylated haplotype would
not be a sufficient change to up-regulate its expression, either. But
the transient CSE treatment (1 day) clearly reduced RUNX3
transcription (Figure 4A). The molecular mechanism of this
transcription down-regulation induced by the transient CSE
treatment is unclear and will require future studies to uncover,
but we can tentatively rule out a mechanism related to gross
changes in DNA methylation.
Both IGF2 and H19 were found to be up-regulated in the
airway epithelial cells after chronic CSE treatment from the monoallelically expressed chromosome with no evidence for loss of
imprinting [8]. In the chronically CSE-treated urothelial cells
however, H19 was down-regulated (Figure 4B). The IGF2-H19
locus is imprinted in normal human bladder epithelial cells [34],
but the data from our untreated control UROtsa cells indicate that
the imprinting is lost in this cell line. The UROtsa was
immortalized by SV40-T and the loss of imprinting at the
IGF2-H19 locus could be caused by SV40-T expression which has
been shown to induce DNA hypermethylation [35]. The loss of
imprinting in the parental UROtsa cells however, does not take

away the validity of the hypomethylation effect of CSE exposure in
the early phases as the non-imprinted RUNX3 also showed this
phenotype.
On the practical application side, one of our intents of the
present study was to identify tumor suppressor gene loci that show
early epigenetic changes in urothelial cells exposed to CSE for use
as potential diagnostic markers. Urothelial cells directly exposed to
CSE, simulating exposure to the systemic soluble contents of
cigarette smoke, have a hypomethylated phenotype in genes that
show hypermethylation in bladder cancers. Efforts directed at
developing epigenetic tests for early detection and diagnosis of
bladder cancer should take this phenomenon under careful
consideration.

Supporting Information
Figure S1 Methyl-Profiler PCR Array analysis of tumor
suppressor gene methylation changes. Genomic DNA
extracted from UROtsa cells chronically treated with CSE,
UROCSE-p32 (32nd passage) and from untreated control cells,
UROtsa-p32 (32nd passage), were applied to the arrays according
to the supplier’s procedures. HM: Hyper-methylated; IM:
Intermediately-methylated; UM: Un-methylated per supplier’s
criteria. Failure: reactions failed to pass the supplier’s quality
control standards.
(TIF)
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